CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the speci...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BRIN, Elena TAO, Xueliang WEBBER, Stephen, E |
| description | The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.
La présente invention concerne la synthèse, des formulations pharmaceutiquement acceptables et des utilisations de composés selon la formule (I), ou d'un stéréo-isomère, d'un tautomère ou d'un sel pharmaceutiquement acceptable de ceux-ci. (Formule I) Pour les composés de Formule (I), R1, R2, R3, Ar et Z sont tels que définis dans la description. Lesdits composés de Formule (I) selon l'invention sont des inhibiteurs de CK2 et s'avèrent utiles dans un grand nombre d'applications thérapeutiques, notamment mais pas exclusivement dans le traitement de troubles proliferatifs tels que le cancer, l'inflammation et les troubles immunologiques. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2017223432A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2017223432A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2017223432A13</originalsourceid><addsrcrecordid>eNrjZDBw9jZS8PTz8HTyDPEPCtZRcPb3DfAP9gzx9PcLVnD0c1HwdQ3x8HcJVgjxcA1y9XfjYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBobmRkbGJsZGjobGxKkCAL0rJx0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF</title><source>esp@cenet</source><creator>BRIN, Elena ; TAO, Xueliang ; WEBBER, Stephen, E</creator><creatorcontrib>BRIN, Elena ; TAO, Xueliang ; WEBBER, Stephen, E</creatorcontrib><description>The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.
La présente invention concerne la synthèse, des formulations pharmaceutiquement acceptables et des utilisations de composés selon la formule (I), ou d'un stéréo-isomère, d'un tautomère ou d'un sel pharmaceutiquement acceptable de ceux-ci. (Formule I) Pour les composés de Formule (I), R1, R2, R3, Ar et Z sont tels que définis dans la description. Lesdits composés de Formule (I) selon l'invention sont des inhibiteurs de CK2 et s'avèrent utiles dans un grand nombre d'applications thérapeutiques, notamment mais pas exclusivement dans le traitement de troubles proliferatifs tels que le cancer, l'inflammation et les troubles immunologiques.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20171228&DB=EPODOC&CC=WO&NR=2017223432A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20171228&DB=EPODOC&CC=WO&NR=2017223432A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BRIN, Elena</creatorcontrib><creatorcontrib>TAO, Xueliang</creatorcontrib><creatorcontrib>WEBBER, Stephen, E</creatorcontrib><title>CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF</title><description>The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.
La présente invention concerne la synthèse, des formulations pharmaceutiquement acceptables et des utilisations de composés selon la formule (I), ou d'un stéréo-isomère, d'un tautomère ou d'un sel pharmaceutiquement acceptable de ceux-ci. (Formule I) Pour les composés de Formule (I), R1, R2, R3, Ar et Z sont tels que définis dans la description. Lesdits composés de Formule (I) selon l'invention sont des inhibiteurs de CK2 et s'avèrent utiles dans un grand nombre d'applications thérapeutiques, notamment mais pas exclusivement dans le traitement de troubles proliferatifs tels que le cancer, l'inflammation et les troubles immunologiques.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDBw9jZS8PTz8HTyDPEPCtZRcPb3DfAP9gzx9PcLVnD0c1HwdQ3x8HcJVgjxcA1y9XfjYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBobmRkbGJsZGjobGxKkCAL0rJx0</recordid><startdate>20171228</startdate><enddate>20171228</enddate><creator>BRIN, Elena</creator><creator>TAO, Xueliang</creator><creator>WEBBER, Stephen, E</creator><scope>EVB</scope></search><sort><creationdate>20171228</creationdate><title>CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF</title><author>BRIN, Elena ; TAO, Xueliang ; WEBBER, Stephen, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2017223432A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BRIN, Elena</creatorcontrib><creatorcontrib>TAO, Xueliang</creatorcontrib><creatorcontrib>WEBBER, Stephen, E</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BRIN, Elena</au><au>TAO, Xueliang</au><au>WEBBER, Stephen, E</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF</title><date>2017-12-28</date><risdate>2017</risdate><abstract>The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.
La présente invention concerne la synthèse, des formulations pharmaceutiquement acceptables et des utilisations de composés selon la formule (I), ou d'un stéréo-isomère, d'un tautomère ou d'un sel pharmaceutiquement acceptable de ceux-ci. (Formule I) Pour les composés de Formule (I), R1, R2, R3, Ar et Z sont tels que définis dans la description. Lesdits composés de Formule (I) selon l'invention sont des inhibiteurs de CK2 et s'avèrent utiles dans un grand nombre d'applications thérapeutiques, notamment mais pas exclusivement dans le traitement de troubles proliferatifs tels que le cancer, l'inflammation et les troubles immunologiques.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2017223432A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A47%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BRIN,%20Elena&rft.date=2017-12-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2017223432A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |